NCT00666965View on ClinicalTrials.gov

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Idiopathic Restless Legs Syndrome
Interventions
DRUG

SPM 962

transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks

Trial Locations (8)

Unknown

Chubu Region

Chugoku Region

Hokkaido Region

Kanto Region

Kinki Region

Kyushu Region

Shikoku Region

Tohoku Region

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY